Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06968338 | A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | PHASE1 | COMPLETED | 88 | — | — | Apr 11, 2025 | Mar 20, 2026 | Apr 23, 2026 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| ARGX-213 | EXPERIMENTAL | Participants receiving the experimental drug |
| Placebo | PLACEBO_COMPARATOR | Participants receiving placebo |
| Name | Type | Description |
|---|---|---|
| ARGX-213 | BIOLOGICAL | Intravenous or subcutaneous administrations of ARGX-213 |
| Placebo | OTHER | Intravenous or subcutaneous administrations of placebo |
Inclusion Criteria: * Is at least the local legal age of consent for clinical studies and is aged 18 to 65 years, inclusive, when signing the ICF * Is a female of nonchild bearing potential (either postmenopausal or surgically sterilized) or a male * Has a body weight between 50 and 100 kg and a BM...